A pharmacogenetic test report tells you how your body is predicted to process certain medications, based on variations in specific genes. The core of most reports is a set of gene names, paired with labels like “normal metabolizer” or “poor metabolizer,” and these labels drive the prescribing recommendations that follow. Understanding what those categories mean, where they come from, and what they leave out can help you have a much more productive conversation with your doctor or pharmacist about what the results actually change for your care.
What You Will See on a Typical Report
Most pharmacogenetic reports, whether from a hospital-affiliated lab or a consumer testing company, share a common structure. For each gene tested, the report will list your genotype (usually written as two “star alleles” separated by a slash, like *1/*2), and then translate that genotype into a predicted phenotype. The phenotype is the part that matters most for prescribing: it tells your clinician how quickly or slowly you are expected to metabolize a particular drug. The star-allele system has been the standard shorthand in pharmacogenomics for decades, used to predict how well a drug will work and whether you are at higher risk of side effects.
Star alleles are named after a gene followed by an asterisk and a number. The *1 allele is typically the “reference” or normal-function version. Higher numbers usually represent variants that change how the enzyme works. Each person carries two copies of most genes (one from each parent), so your result is a pair: your diplotype. A result of CYP2D6 *1/*4, for instance, means one copy is normal-function and the other is non-functional. Each allele gets assigned a numerical activity score, and summing the two gives your overall activity score, which in turn maps to a phenotype category.
For the gene CYP2D6, one of the most commonly tested, alleles are grouped by function: non-functional alleles (like *3, *4, *5, *6) get an activity value of zero, decreased-function alleles (like *9, *10, *17, *41) get 0.5, normal-function alleles (like *1, *2, *35) get 1, and increased-function alleles with gene duplications (like *1xN, *2xN) get 2.1Genetics in Medicine. Prediction of CYP2D6 phenotype from genotype across world populations If your two alleles add up to zero, you are a poor metabolizer. If they add up to around 1, you are an intermediate metabolizer. A score of 1.5 to 2 is normal, and scores above 2 suggest ultrarapid metabolism. Your report may show this math explicitly or may skip straight to the phenotype label.
What the Metabolizer Categories Actually Mean
The phenotype label is where the rubber meets the road. Most reports sort you into one of four buckets for each gene:
- Poor metabolizer: Your enzyme has little or no activity. Drugs broken down by that enzyme build up to higher levels in your blood, raising the risk of side effects. For “prodrugs” that need to be activated by the enzyme, you may get little or no therapeutic benefit.
- Intermediate metabolizer: Your enzyme works, but at reduced capacity. Effects are similar to the poor metabolizer category but less extreme.
- Normal metabolizer: Sometimes called “extensive metabolizer” on older reports. Standard drug doses are expected to work as intended.
- Ultrarapid metabolizer: Your enzyme is unusually active, often because you carry extra copies of the gene. You may clear drugs too fast for them to work, or you may convert a prodrug into its active form so quickly that you experience toxicity at normal doses.
These categories are not pass/fail. Being an intermediate metabolizer for one gene does not mean every drug affected by that gene needs to change. Guidelines weigh the size of the effect, the drug’s safety margin, and whether alternatives exist. A drug with a wide safety window might be fine at a standard dose even for a poor metabolizer, while a drug with a narrow window could be dangerous.
Common Genes and the Drugs They Affect
Your report will likely cover several genes. Here are some of the most clinically relevant ones and what they mean in practice.
CYP2D6
This gene encodes an enzyme responsible for metabolizing a wide range of medications, from antidepressants and antipsychotics to certain pain medications and the breast cancer drug tamoxifen. Tamoxifen is a prodrug, meaning your body has to convert it into a more active form. If you are an intermediate or poor CYP2D6 metabolizer, your body may not make enough of that active metabolite, which could make the treatment less effective.2PubMed. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy CYP2D6 is also one of the trickiest genes to test accurately, because it sits next to a very similar “pseudogene” (CYP2D7) that can confuse standard testing platforms. Newer long-read sequencing approaches are being developed to catch gene deletions and duplications that older tests sometimes miss.3The Pharmacogenomics Journal. Amplicon-based long-read sequencing for accurate CYP2D6 gene deletion and duplication detection using CYP2D7 as a reference gene
CYP2C19
This gene matters most for people taking clopidogrel (Plavix), a blood thinner commonly prescribed after heart attacks and strokes. CYP2C19 also affects the metabolism of certain antidepressants, anti-anxiety medications, and proton pump inhibitors (PPIs) like omeprazole. Among stroke patients prescribed antiplatelet therapy, roughly four out of five were also taking at least one other CYP2C19-metabolized drug, most commonly a PPI.4PubMed. Exposure to CYP2C19-metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing If you are a poor metabolizer for CYP2C19, clopidogrel may not be activated properly, potentially raising your risk of cardiovascular events. On the other hand, carrying certain gain-of-function alleles can increase the drug’s effects.5Die Pharmazie – An International Journal of Pharmaceutical Sciences. CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs
CYP2C9 and VKORC1
These two genes are tested together for people taking warfarin, one of the oldest and most widely used blood thinners. VKORC1 affects how sensitive you are to warfarin’s effects, while CYP2C9 affects how fast you clear it. In one study of patients on warfarin, those with the normal (wild-type) genotype needed the highest average daily dose, while those with a VKORC1 variant needed a lower dose to stay in the therapeutic range. Patients carrying the VKORC1 variant were also far more likely to overshoot the target blood-thinning level.6PubMed. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients If your report includes these genes, the results help your doctor fine-tune your warfarin dose to reduce the risk of dangerous bleeding or clotting.
DPYD
This gene matters if you are receiving fluoropyrimidine chemotherapy drugs like 5-fluorouracil or capecitabine, which are used for several types of cancer. The DPYD gene controls the enzyme that breaks down these drugs. If the enzyme is deficient, the drugs can accumulate to toxic levels, sometimes with fatal consequences. Four specific DPYD variants have been identified as predictors of severe toxicity from fluoropyrimidine therapy.7PubMed Central. Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis Research supports DPYD genotyping as a useful screening step before starting these drugs.8PubMed Central. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis In some countries, DPYD testing before fluoropyrimidine treatment is now standard practice. Even so, rare variants beyond the well-known four can also cause deficiency, and testing panels are still catching up.9The Pharmacogenomics Journal. Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity
HLA Genes
Unlike the CYP enzymes, which affect how fast you process a drug, HLA gene variants predict whether you might have a severe immune-mediated reaction to specific medications. HLA-B*57:01 is tested before prescribing abacavir (an HIV drug) to prevent hypersensitivity reactions. HLA-B*15:02 is tested before carbamazepine (a seizure and mood-stabilizing medication) because carriers face a heightened risk of a dangerous skin reaction called Stevens-Johnson syndrome.10PubMed Central. HLA Association with Drug-Induced Adverse Reactions For HLA results, the report is essentially binary: you either carry the risk allele or you do not. If you carry it, the drug should generally be avoided entirely rather than adjusted in dose.
Where the Guidelines Come From
If your report includes specific drug recommendations, those likely originate from one of two main sources: the Clinical Pharmacogenetics Implementation Consortium (CPIC) or the FDA’s Table of Pharmacogenetic Associations. CPIC publishes peer-reviewed guidelines that translate diplotypes into phenotypes and then into dosing recommendations, using a standardized system for grading the strength of evidence.11PubMed Central. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process The FDA also maintains its own table classifying gene-drug pairs by the type of action recommended. These two resources do not always agree. A comparison found that the FDA’s classification of drugs does not consistently line up with CPIC’s actionability levels.12PubMed Central. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines This is not necessarily alarming: the two bodies use different frameworks and update on different schedules. But it does mean that two reports using different guideline sources might phrase their recommendations differently for the same result. If you see a discrepancy, ask your pharmacist which guideline set your lab follows.
Why Your Genetics Are Not the Whole Story
One of the most common misconceptions about pharmacogenetic testing is that the result is a permanent, unchanging prediction of how every drug will affect you. Your genotype does not change, but your actual drug-metabolizing capacity can shift depending on what else is going on in your body.
The most important confounder is something called phenoconversion: when another drug you are taking inhibits or ramps up the very enzyme your test measured. In other words, even if your genes say you are a normal metabolizer, a strong enzyme inhibitor taken alongside the target drug can functionally turn you into a poor metabolizer. Research on CYP2C19 found that the antifungal voriconazole converted half of genetically normal metabolizers into intermediate or poor metabolizers, while the antidepressant fluvoxamine converted all subjects into a reduced-activity phenotype.13PubMed Central. The impact of CYP2C19 genotype on phenoconversion by concomitant medication A study of patients on antidepressants found phenoconversion rates between a third and two-thirds of patients across different CYP enzymes, with a significant overall reduction in enzyme activity compared to what the genotype alone would predict.14PubMed. Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants
Beyond drug interactions, age, sex, liver health, and kidney function all influence how your body handles medications. These factors are not captured by a DNA test. Your pharmacogenetic result should be treated as one input among several, not as a standalone instruction sheet.
Clinical Tests Versus Direct-to-Consumer Reports
Not all pharmacogenetic tests are created equal. Clinical tests ordered by a healthcare provider tend to use validated panels, report results in formats that clinicians can act on, and are sometimes integrated directly into your electronic health record. Some hospitals have built clinical decision support systems that automatically flag gene-drug interactions when a doctor writes a prescription, making the results part of the workflow rather than a separate document to consult.15PubMed Central. Integrating pharmacogenomics into electronic health records with clinical decision support At the NIH Clinical Center, for example, the system checks whether a patient has an HLA test result on file before allowing certain high-risk prescriptions to go through, and can block the order if the genotype predicts a dangerous reaction.16PubMed Central. Integrating pharmacogenetic information and clinical decision support into the electronic health record
Direct-to-consumer (DTC) companies like 23andMe also offer pharmacogenetic results, but coverage and quality vary. An analysis of 23andMe’s pharmacogenetic offerings found that the clinical validity and utility differed extensively between tests, and that the variants tested may have different sensitivity across populations because of differing allele frequencies and linkage patterns.17PubMed Central. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe A DTC test might correctly identify that you carry one well-known variant but miss a rarer one that a clinical panel would catch. If you are making medication decisions based on DTC results, confirm the findings with your prescriber and ask whether clinical-grade testing is warranted.
Why Your Ancestry Matters for Accuracy
Pharmacogenetic research has historically been heavily skewed toward people of European descent, and this gap has real consequences for how well a test performs depending on who you are. Allele frequencies for pharmacogenes differ substantially across populations. A large study looking at nine biogeographic groups found that nearly 200 alleles were detected in underrepresented groups that were not found at all in the largest reference group. All but two of the nine groups were underrepresented in existing pharmacogenetic data.18PubMed Central. Patterns of pharmacogenetic variation in nine biogeographic groups
This is not just an abstract concern. When researchers looked at clopidogrel users in a hospital biobank, patients of Asian ancestry had significantly higher rates of CYP2C19 alleles that could change how the drug works compared to patients of European ancestry.19PubMed Central. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population If a test panel was designed primarily to catch variants common in European populations, it could miss variants that matter in other groups. The star-allele system itself runs into problems here, because the discovery of rare variants through modern genome sequencing has introduced complexities that the traditional system was not designed to handle.20PubMed Central. Contradiction in Star-Allele Nomenclature of Pharmacogenes between Common Haplotypes and Rare Variants If your ancestry is from a population that is underrepresented in pharmacogenetic databases, your results carry a slightly wider margin of uncertainty, and that is worth flagging with your provider.
What to Do After You Get Results
A pharmacogenetic report is not a prescription. It does not tell you to stop or start any medication on your own. In a study tracking what people did after receiving direct-to-consumer genetic results, about 6% of participants reported changing a prescription medication within six months. Of those, the vast majority consulted a healthcare provider before making a change.21PubMed Central. Prescription medication changes following direct-to-consumer personal genomic testing: Findings from the Impact of Personal Genomics (PGen) Study That is the right instinct. A doctor or pharmacist can look at your full medication list, your other health conditions, and your genotype together and decide whether a dose change, a drug switch, or no change at all is the right call.
Keep a copy of your results somewhere accessible. Your genotype does not expire, and the results could be relevant years from now if you are prescribed a new medication that interacts with one of the genes tested. Some health systems are starting to store pharmacogenetic results in the electronic health record so they automatically inform future prescribing decisions.15PubMed Central. Integrating pharmacogenomics into electronic health records with clinical decision support If your system does not do this yet, keeping a printed or digital copy in your medical file is a low-effort safeguard.
Cost and Insurance Coverage
One practical question many people have is whether pharmacogenetic testing is worth the cost, and whether insurance will cover it. The evidence leans in favor of testing, at least for certain drugs. A systematic review of over 100 economic studies evaluating pharmacogenetic testing for drugs with CPIC guidelines found that roughly seven out of ten studies showed testing was either cost-effective or actually cost-saving. Clopidogrel had the strongest economic evidence, with nearly all studies showing favorable results. HLA testing before prescribing abacavir, allopurinol, or carbamazepine was also frequently found to be cost-effective. Antidepressant-related testing showed favorable economics in most studies as well.22PubMed Central. Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review Insurance coverage remains inconsistent. Some payers cover testing when there is a clear clinical indication, like starting a new medication with known pharmacogenetic interactions, while others consider it investigational. If you are uncertain about coverage, ask your prescriber to document the clinical rationale when ordering the test, as this strengthens the case for reimbursement.
When a Normal Result Does Not Mean “No Risk”
Getting a “normal metabolizer” result across the board can feel reassuring, but it is worth understanding what that label does and does not guarantee. First, any test only checks for the variants on its panel. If you carry a rare variant that was not tested for, you could still have altered enzyme function. Researchers studying DPYD, for instance, found that integrating sequencing beyond the standard four tested variants helped identify additional patients at risk for chemotherapy toxicity.9The Pharmacogenomics Journal. Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity Second, as discussed earlier, phenoconversion from other medications, liver impairment, or age-related changes can shift your actual enzyme activity away from what your genes predict. Third, pharmacogenetics explains only one dimension of how a drug affects you. Factors like kidney function, body weight, diet, and adherence all play a role that genetics cannot capture.
A “normal” result means the test did not find a reason to deviate from standard prescribing for the variants it checked. It does not mean every drug will work perfectly or that side effects are impossible. Keeping that distinction in mind helps set realistic expectations for what the test can and cannot do.